百普赛斯涨0.18%，成交额1.50亿元，今日主力净流入613.13万

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively developing products related to monkeypox and has a strong focus on recombinant proteins and cell immunotherapy, benefiting from the depreciation of the RMB and its recognition as a "specialized and innovative" enterprise [2][3][4]. Group 1: Company Performance - On February 6, the company's stock rose by 0.18%, with a trading volume of 150 million yuan and a turnover rate of 2.39%, bringing the total market capitalization to 8.304 billion yuan [1]. - For the period from January to September 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [9]. Group 2: Product Development and Market Position - The company has initiated the development of products related to monkeypox virus and has launched multiple recombinant proteins, antibodies, and test kits to support vaccine and therapeutic drug development [2]. - The company has developed high-quality recombinant proteins targeting various disease markers, fulfilling the needs of biopharmaceutical research and production [2]. - The company has introduced a specific antibody targeting the CD19 antigen, enhancing the detection methods for CAR-T cell therapy, and is expanding its product offerings related to cell and gene therapy [2]. Group 3: Industry Recognition and Financial Impact - The company has been recognized as a national-level "specialized and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [3]. - The company's overseas revenue accounted for 66.46% of its total revenue, benefiting from the depreciation of the RMB [4]. - The company operates in the pharmaceutical and biotechnology sector, focusing on antigen detection, monkeypox, Alzheimer's, and cell immunotherapy [9].